substantially modified ratios of effector to regulatory t cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion implications for immunotherapy大幅修改率效应的调节性t细胞在卵巢癌患者化疗期间回到预处理水平完成对免疫治疗的影响.pdfVIP

Cancers 2012, 4, 581-600; doi:10.3390/cancers4020581 OPEN ACCESS cancers ISSN 2072-6694 /journal/cancers Article Substantially Modified Ratios of Effector to Regulatory T Cells During Chemotherapy in Ovarian Cancer Patients Return to Pre-Treatment Levels at Completion: Implications for Immunotherapy Anthony Park 1,†, Chindu Govindaraj 1,†, Sue D. Xiang 1,*, Julene Halo 2, Michael Quinn 2, Karen Scalzo-Inguanti 1,† and Magdalena Plebanski 1,†,* 1 Department of Immunology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria 3004, Australia; E-Mails: Anthony.Park@ (A.P.); Chindu.Govindaraj@ (C.G.); Karen.Scalzo@.au (K.S.-I.) 2 Department of Oncology, Royal Women’s Hospital, Melbourne, Victoria 3052, Australia; E-Mails: Julene.Hallo@.au (J.H.); QuinnM@.au (M.Q.) † These authors contributed equally to this work. * Authors to whom correspondence should be addressed; E-Mails: Sue.Xiang@ (S.X.); Magdalena.Plebanski@ (M.P.); Tel.: +61-3-9903-0627 (S.X.); Fax: +61-3-9903-0038 (S.X.). Received: 18 May 2012; in revised form: 13 June 2012 / Accepted: 14 June 2012 / Published: 18 June 2012 Abstract: Ovarian cancer is the leading cause of death from gynaecological malignancy. Despite improved detection and treatment options, relapse rates remain high. Combining immunotherapy with the current standard treatments may provide an improved prognosis, however, little is known about how standard chemotherapy affects immune potential (particularly T cells) over time, and he